Neuroendocrine Deficits and Weight Development Before and After Proton Therapy in Children With Craniopharyngioma.

in Clinical oncology (Royal College of Radiologists (Great Britain)) by M Bischoff, J Beckhaus, D A Khalil, F Sen, S Frisch, B Koska, C Kiewert, B Bison, R-D Kortmann, C Friedrich, H L Müller, B Timmermann

TLDR

  • The study investigated the effect of proton beam therapy on endocrine morbidity and obesity in pediatric patients with craniopharyngioma.
  • The results suggest that multifactorial analysis is necessary to improve treatment strategies.

Abstract

Our objective was to analyse tumour- and treatment-related factors influencing endocrine morbidity and obesity pre- and post-proton beam therapy (PBT) in paediatric patients with craniopharyngioma. A total of 65 patients at the onset of PBT were included in the analysis within our prospective registry study. The data pertaining to endocrine deficits and BMI prior to PBT were retrieved from the medical records on a retrospective basis. Cumulative incidences (CI) of endocrinopathies, age- and sex-adjusted BMI standard deviation scores (BMI-SDS) were calculated. Before PBT, 90.8% had ≥1 neuroendocrine deficit. Diabetes insipidus (DI) was attributed to surgery in 96%. Patients with postoperative DI had a higher 3-year CI of adrenocorticotropic hormone and thyroid-stimulating hormone deficiency rates compared to those without DI (p < .001). At PBT start, 47.7% had already panhypopituitarism compared to 67.7% at the last follow-up (FU). Median FU post-PBT was 3.2 years (range, 1.0-9.6). Post-PBT, 38.2% remained free of additional hormone deficiencies. A trend towards lower endocrine morbidity scores for patients who received PBT during their primary treatment compared to irradiation at progression did not reach statistical significance (p = .068). The BMI-SDS increase from diagnosis to the start of radiotherapy was significantly greater than from the start of PBT to the end of FU (mean BMI-SDS increase: 0.61, ±1.16 vs. 0.13, ±0.84, p = 0.019), with a median time of 10.2 and 38.4 months, respectively. In the multivariate analysis, hypothalamic involvement (p = .042) and the BMI-SDS level at diagnosis (p = .006) were identified as clinical factors indicating severe obesity at FU (BMI-SDS ≥+2). Panhypopituitarism is frequently observed in paediatric patients with craniopharyngioma prior to PBT. The potential benefits of early PBT on endocrine outcomes require further investigation through longer FU periods. The greatest increase in weight occurred before radiotherapy. Endocrine deficiencies and weight gain are multifactorial and require close monitoring.

Overview

  • The study aimed to investigate tumour- and treatment-related factors influencing endocrine morbidity and obesity in pediatric patients with craniopharyngioma treated with proton beam therapy (PBT).
  • The study included 65 patients prospectively enrolled and analyzed their endocrine deficits and body mass index (BMI) pre- and post-PBT.
  • The primary objective was to identify clinical factors influencing endocrine morbidity and obesity in pediatric patients with craniopharyngioma treated with PBT.

Comparative Analysis & Findings

  • Cumulative incidence of endocrinopathies increased over time, with 47.7% having panhypopituitarism at PBT start and 67.7% at last follow-up.
  • Diabetes insipidus (DI) attributed to surgery was associated with a higher rate of adrenocorticotropic hormone and thyroid-stimulating hormone deficiency.
  • There was no significant difference in endocrine morbidity scores between patients receiving PBT during primary treatment versus irradiation at progression.

Implications and Future Directions

  • The study highlights the importance of close monitoring of endocrine deficiencies and weight gain in pediatric patients with craniopharyngioma.
  • Longer follow-up periods are needed to investigate the potential benefits of early PBT on endocrine outcomes.
  • Multifactorial analysis of clinical factors influencing endocrine morbidity and obesity is required to improve treatment strategies.